4 active not recruiting, 2 recruiting, 1 not yet recruiting. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 4, Recruiting 2, Not yet recruiting 1 |
Follow Tarlatamab: new trials by email Literature Review of Tarlatamab trials Research Report on Tarlatamab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer Tarlatamab, Durvalumab - Limited Stage Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | PrECOG, LLC. | 430 | 2027-01-01 | 2026-06-09 |
| Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Tarlatamab - Small Cell Lung Cancer | Phase 3 | Recruiting | Amgen | 400 | 2026-08-28 | 2026-09-17 |
| Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs) Standard of Care Chemotherapy, Tarlatamab - Neuroendocrine Carcinoma | Phase 3 | Recruiting | Intergroupe Francophone de Cancerologie Thoracique | 129 | 2026-02-06 | 2026-02-11 |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) Tarlatamab, Durvalumab, Carboplatin - Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 350 | 2025-08-18 | 2026-09-08 |
| Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab Tarlatamab, Durvalumab - Extensive-Stage Small-Cell Lung Cancer, Small-Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 563 | 2024-06-05 | 2026-11-06 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Tarlatamab, Placebo - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 404 | 2024-02-20 | 2026-04-29 |
| Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer Tarlatamab, Lurbinectedin, Topotecan - Small Cell Lung Cancer (SCLC) | Phase 3 | Active not recruiting | Amgen | 509 | 2023-05-31 | 2026-01-05 |
Small Cell Lung Carcinoma (6) · Carcinoma, Neuroendocrine (1)
Amgen (5) · Intergroupe Francophone de Cancerologie Thoracique (1) · PrECOG, LLC. (1)
Australia (5) · China (5) · France (5) · Japan (5) · Switzerland (5) · United States (5) · Argentina (4) · Austria (4) · Belgium (4) · Brazil (4) · Germany (4) · Greece (4) · Italy (4) · Mexico (4) · Poland (4)
PMID 39530627, PMID 40934933, PMID 42377743, PMID 42929702
2023 (2)